Cardiac Contractility Modulation: Mechanisms of Action in Heart Failure with Reduced Ejection Fraction and Beyond
Key result
Cardiac contractility modulation improves symptoms, exercise tolerance, and quality of life, and reduces heart failure hospitalizations in patients with ejection fractions between 25% and 45%.
Why the study?
Despite progress in treating HFrEF, morbidity and mortality remain substantial, prompting a review of cardiac contractility modulation across the heart failure ejection fraction spectrum.
Does cardiac contractility modulation improve symptoms and reduce heart failure hospitalizations in patients with heart failure?
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Supports CCM consideration in selected HFrEF/HFmrEF patients; leaves open need for prospective RCTs across EF spectrum.
Structured PICO
Does cardiac contractility modulation improve symptoms and reduce heart failure hospitalizations in patients with heart failure?
P
Population
Patients with heart failure, specifically those with ejection fractions between 25% and 45% and normal or slightly prolonged QRS duration.
I
Intervention
Cardiac contractility modulation (CCM) signals (biphasic high-voltage bipolar signals delivered to the right ventricular septum during the absolute refractory period)
CCM is a promising device-based therapy that improves symptoms and reduces hospitalizations in HFrEF and HFmrEF patients, with potential applications across the entire EF spectrum.
Cite This Study
Tschöpe et al. (2018) conducted a review in Heart failure. Cardiac contractility modulation (CCM) was evaluated. Cardiac contractility modulation improves symptoms, exercise tolerance, and quality of life, and reduces heart failure hospitalizations in patients with ejection fractions between 25% and 45%.